Kristi Rosa

Faculty from the George Washington Cancer Center to shed light on some of the current and future research efforts being made at their institution.

Shiven B. Patel, MD, MBA, FACP, provides insight into key trials in squamous non–small cell lung cancer and how to apply the data to practice.

Clarke A. Low, MD, discusses the role of osimertinib in EGFR-mutated non–small cell lung cancer and emerging research efforts in the paradigm.

Sonam Puri, MD, discusses key trials in metastatic nonsquamous disease and highlights ongoing research generating excitement in the space.

Leading oncology experts at the University of California, Los Angeles share the pivotal research being conducted at their institution.

Faculty from Texas Oncology and Quest Med Fusion highlight exciting ongoing research efforts at their respective institutions.

Chen Fu, MD, discusses the data supporting the use of CT-P6 in HER2-positive breast cancer, the benefits to bringing more biosimilars to the market, and the future that these products have in oncology.

Faculty from Duke Cancer Institute provide insight into the exciting breast cancer research being conducted at their institution.

Alberto Chiappori, MD, discusses emerging biomarkers in non–small cell lung cancer and the different ways to test for them.

Donald A. Richards, MD, PhD, highlights the key takeaways from the pivotal POLO trial and underscores the importance of genetic testing in metastatic pancreatic cancer.

Early data suggest that afatinib (Gilotrif) is a potentially effective treatment option for patients with lung adenocarcinoma who have NRG1 fusions, but the identification of these fusions continues to pose a challenge.

Thought leaders from NYU Langone’s Perlmutter Cancer Center highlight the latest groundbreaking breast cancer research being conducted at their institution.

The addition of the antibody-drug conjugate brentuximab vedotin and the PD-1 inhibitor nivolumab to chemotherapy in patients with stage I/II Hodgkin lymphoma is under investigation in an ongoing phase II trial (NCT03233347).

Experts from City of Hope share insight on some of the pivotal research being conducted at their institution.

Petros Grivas, MD, highlights the evolving role of immunotherapy in bladder cancer and ongoing research slated to further progress along.

The tumor-infiltrating lymphocyte therapy LN-145 induced promising response rates with acceptable safety in patients with recurrent, metastatic, or persistent cervical cancer—a patient population of great unmet need.

Linda R. Duska, MD, discusses the ongoing debate between upfront surgery and neoadjuvant chemotherapy in ovarian cancer and the data that support both options.

The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer.

At the 2019 OncLive® State of the Science Summit™ on Ovarian Cancer, we asked experts from the University of Pittsburgh Medical Center about the intriguing research being conducted at their institution.

John Comerci, Jr, MD, provides an overview of advances made in ovarian cancer and remaining challenges to address with future research.

Lan G. Coffman, MD, PhD, discusses pivotal trials evaluating frontline maintenance therapy in advanced ovarian cancer and unanswered questions that still need to be addressed with future research.

Data from several clinical trials support treatment with lenalidomide (Revlimid) plus low-dose dexamethasone in select patients with high-risk smoldering multiple myeloma to prevent disease progression and other promising combinations under investigation are showing curative potential.

The emergence of monoclonal antibodies, immunomodulatory agents, immunotoxins, bispecific T-cell engagers, and CAR T-cell therapies will redefine multiple myeloma treatment. However, these new approaches, by themselves, are not enough to achieve cure; they must be used in combination.

The goal of induction regimens for patients with newly diagnosed multiple myeloma is to reduce the burden of disease and prolong durability of response and overall survival, while minimizing toxicity.

Conor E. Steuer, MD, discusses emerging agents in the treatment of patients with ALK- or ROS1-positive non–small cell lung cancer and the sequencing challenges that have resulted in the space.

Experts from Emory University School of Medicine, Massachusetts General Hospital, and Hospital of the University of Pennsylvania, highlight the exciting research being conducted at their respective institutions.

Manali Bhave, MD, highlights the novel agents under investigation in the treatment of patients with metastatic HER2-positive breast cancer.

Benjamin Weinberg, MD, provides insight into NRG1 fusions, the effectiveness of afatinib in patients harboring these fusions, and future research being done in NRG1 fusion–positive gastrointestinal cancers.

David Samuel Dicapua Siegel, MD, highlights key research in multiple myeloma and the renewed focus on improving quality of life.

Jane Meisel, MD, provides insight on how genomic assays are helping to individualize treatment plans and strategies to determine the optimal duration of endocrine therapy.